Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07501702 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07501702 is a Phase 2 study that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 30 participants.
The verdict
NCT07501702, a Phase 2 study, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Interventions
- DRUG Placebo
- DRUG Povetacicept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-05-13 |
| Est. Completion | 2029-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07501702
The ClinicalTrials.gov registry entry for NCT07501702 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07501702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07501702 about?
NCT07501702 is a clinical study titled "A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis". The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
What is the current status of trial NCT07501702?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-05-13. Estimated completion is 2029-03-02.
What interventions are being tested in trial NCT07501702?
The interventions under investigation include: Placebo (DRUG), Povetacicept (DRUG).
Who is sponsoring clinical trial NCT07501702?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.